NCT04211480View on ClinicalTrials.gov

Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

October 15, 2023

Study Completion Date

November 27, 2023

Conditions
β Thalassemia Major
Interventions
BIOLOGICAL

γ-globin reactivated autologous hematopoietic stem cells

gene edited autologous hematopoietic stem cells with γ-globin expression

Trial Locations (1)

200241

Shanghai Bioray Laboratories Inc., Shanghai

Sponsors
All Listed Sponsors
collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT04211480 - Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells | Biotech Hunter | Biotech Hunter